Allergy and Immunology Billing, Measured Dose by Dose
Allergy and immunology revenue comes from testing panels, immunotherapy vial preparation and administration under component coding, biologic and IVIG injection, and the medical-necessity and dose-limit rules that gate every line. ProvidaRCM runs the full medical billing service cycle for allergy and immunology practices, from eligibility verification and prior authorization through component coding, claims, and denial recovery.
Allergy and Immunology Services We Bill
From a percutaneous skin-prick panel through subcutaneous immunotherapy vial preparation, biologic injection, IVIG infusion, and food and drug challenge, we bill the full range of specialty billing services allergy and immunology practices deliver, under the correct coding model for each.
Subcutaneous Immunotherapy, Vial Prep and Administration
The revenue backbone of an allergy practice. Under Medicare component coding, the extract preparation is billed with 95144 for a single-dose vial or 95165 per cc for a multi-dose vial, and the administration is billed separately with 95115 for a single injection or 95117 for two or more. We track the 95165 units against the vial limit and the Medicare medically unlikely edit, and we support every unit with the signed extract order.
Allergy Skin Testing
Percutaneous, or skin-prick, testing with 95004 per test and intracutaneous testing with 95028 per test, each tied to a documented relevant allergen rather than a blanket panel.
Patch Testing
Patch application testing for contact dermatitis, reported per patch with 95044 and photo-patch with 95052, each patch tied to a relevant allergen from the exposure history.
Sublingual Immunotherapy
SLIT is frequently a non-covered benefit under Medicare and many commercial plans. We verify the coverage before treatment and handle non-covered SLIT with a patient agreement instead of a denied claim.
Biologic Injection
Therapeutic subcutaneous biologics such as omalizumab and mepolizumab, administered under 96372 with the drug reported on its HCPCS J-code, prior authorization obtained where required.
IVIG Infusion
Intravenous immune globulin for immunodeficiency, infused under 96365 for the first hour and 96366 for each additional hour, with the immune globulin reported on its HCPCS J-code and prior authorization on file.
Asthma Evaluation and PFTs
Spirometry 94010 and pre and post bronchodilator responsiveness 94060 for asthma severity and control, with the ICD-10 asthma code carried to support medical necessity.
Drug Challenge and Desensitization
Drug allergy testing and desensitization with 95017 and 95018, with the drug, the indication, and the observation plan documented to support medical necessity.
Food Challenge
Oral food challenge with 95075 for a single food and 95076 for each additional food, with the suspected allergy and the medical necessity documented for each challenge.
Venom Immunotherapy
Hymenopteran venom immunotherapy with 95145 for the first venom and 95146 through 95149 for each additional venom, each extract prepared from the patient's specific venom mix under component coding.
In-Vitro Allergy Testing
Allergen-specific IgE serology with 86003 per allergen and 86005 for a multiallergen screen, where the payer prefers in-vitro over skin testing, each tied to a documented relevant allergen.
Allergy and Immunology Code Reference
The CPT, HCPCS, and ICD-10-CM codes an allergy and immunology practice bills most often, grouped by category. Codes must always be supported by provider documentation and verified against the current published code sets.
| Code | Description | Billing Consideration |
|---|---|---|
| 95004 | Percutaneous tests, prick, puncture, or scratch, with allergenic extracts, immediate reaction, per test | Reported per test, each tied to a documented relevant allergen. Blanket panels without clinical indication deny for medical necessity. |
| 95028 | Intracutaneous tests with allergenic extracts, immediate reaction, per test | Step-up testing used when a percutaneous test is negative or indeterminate but clinical suspicion remains high. Document the rationale. |
| 95044 | Patch or application test, including removal, per patch or application | Used for contact dermatitis. Each patch corresponds to a relevant allergen from the exposure history, not a generic panel. |
| 95052 | Photo-patch test, including removal, per patch | Photo-patch testing for photo-contact dermatitis. Reported per patch, with the photo-exposure history documented. |
| 95075 | Oral food challenge, single food | Single-food oral challenge, with the suspected food allergy and the medical necessity documented before the challenge. |
| 95076 | Oral food challenge, each additional food, each 15 minutes | Add-on for each additional food challenged the same session. Reported with 95075, not alone. |
| 95017 | Allergy testing, drug, non-chemotherapeutic | Drug allergy testing. Document the drug, the indication, and the observation plan. Verify the current CPT description. |
| 95018 | Drug desensitization | Drug desensitization procedure. Requires medical necessity, observation documentation, and a supported clinical indication. |
Code sets are updated annually and must be verified against the current published versions and supported by provider documentation. Requirements may vary by payer, plan, and applicable regulations.
Immunotherapy and the 95165 Dose Rule
95165 is billed per cc of prepared multi-dose extract, and every unit has to clear the vial limit, the Medicare medically unlikely edit, and the signed extract order. Component coding splits the preparation from the administration, and the dose rule is where most immunotherapy revenue leaks.
Testing Medical Necessity and Panel Limits
Testing codes are reported per test or per patch, not as a blanket panel. Each test has to tie to a documented relevant allergen, and the step-up tests need a documented rationale. Blanket panels and unsupported step-ups are the most common testing denials.
Skin-Prick Testing, Per Test
Reported per test, with each test tied to a documented relevant allergen based on the patient's exposure history and clinical indication.
Step-Up Intracutaneous Testing
Used when a percutaneous test is negative or indeterminate but the clinical suspicion remains high. Not a first-line panel, and not reported alongside 95004 for the same allergen without a documented reason.
Patch Testing for Contact Dermatitis
Reported per patch applied, including removal and interpretation, for contact dermatitis evaluation. Each patch corresponds to a relevant allergen from the exposure history.
Food and Drug Challenge
Oral food challenge and drug challenge or desensitization, each with the suspected allergy, the drug or food, and the observation plan documented to support medical necessity.
Allergy and Immunology Denial Patterns We Fix
Allergy and immunology denials cluster around immunotherapy dose units, component versus complete coding, testing medical necessity, SLIT coverage, IVIG prior authorization, and biologic necessity. We prevent each pattern before submission and recover the ones already on the books.
Testing panels billed without medical necessity
Blanket 95004 panels of 20 or 40 tests go out with no documented relevant allergen per test, and the payer denies the whole panel.
95165 units exceed the vial or MUE limit
95165 is billed for more units than the vial supports, or above the 30-unit Medicare medically unlikely edit, and the excess units deny.
Administration billed with complete codes instead of component
Under Medicare, 95115 or 95117 administration is billed with 95144 or 95165 preparation as separate components. Billing a complete code instead denies or recoups.
SLIT submitted as a covered service
Sublingual immunotherapy is frequently non-covered under Medicare and many commercial plans. Submitting it as covered denies, and the patient is left with no notice.
IVIG prior authorization missing or necessity undocumented
IVIG infusion goes out without prior authorization, or the immunodeficiency diagnosis that supports medical necessity is not documented, and the claim denies.
Biologic injection medical necessity unsupported
A biologic such as omalizumab is administered without the asthma severity or prior authorization that supports it, and the J-code and the administration deny.
Anaphylaxis and observation documentation missing
A food or drug challenge is performed, but the observation plan and any anaphylaxis response are not documented, and the challenge line denies.
Testing frequency exceeded
Repeat skin testing is billed outside the payer's frequency window, and the second panel denies as a frequency exclusion.
How We Run Your Allergy Revenue Cycle
A six-step lifecycle built around eligibility and prior authorization, documented testing relevance, component versus complete coding, the 95165 dose and MUE limits, and denial prevention.
Verify and authorize
Eligibility confirmed, prior authorization handled for IVIG and biologic therapy, SLIT coverage verified, and the payer's component versus complete coding model confirmed on the eligibility check.
Document testing relevance and order
Each 95004 tied to a documented relevant allergen, the 95028 step-up rationale recorded, the patch exposure history documented, and the signed immunotherapy extract order on file.
Code component versus complete correctly
95144 or 95165 preparation billed with 95115 or 95117 administration under component coding, or the complete code where the payer requires it, with the correct model applied per payer.
Submit within dose and MUE limits
95165 units billed at the anticipated doses, tracked against the vial limit and the 30-unit Medicare edit, with biologics and IVIG sent with prior authorization and the supporting J-code.
Post and reconcile units to the EOB
Payment posting against the EOB, 95165 units reconciled to the paid and denied lines, biologic and IVIG J-codes reconciled to the product administered, and the patient portion billed clearly.
Appeal and prevent
Denial recovery with root-cause analysis, so a denied 95165 unit, a component coding mismatch, or an unsupported testing panel is appealed and prevented on the next cycle.
ProvidaRCM vs Generic Billing Companies
Allergy and immunology is not a generalist practice with a skin-prick panel added. The difference shows up in component coding, the 95165 dose rule, IVIG authorization, and testing medical necessity.
Is Your Allergy Practice Leaking Immunotherapy Revenue?
If any of these are true, your current billing is quietly costing you across immunotherapy, testing, IVIG, and biologics. A free audit will show exactly how much.
Allergy and Immunology Billing Questions, Answered
Filter by the part of the workflow you are asking about, testing, immunotherapy, biologics and IVIG, or coverage, and find the answer that fits your practice.
95004 is reported per percutaneous, or skin-prick, test performed, with each test tied to a documented relevant allergen rather than a blanket panel. We verify the allergen list against the clinical indication, support each test with medical necessity, and confirm the unit count matches the number of tests documented in the record.
95028, intracutaneous testing per test, is used when a percutaneous test is negative or indeterminate but the clinical suspicion remains high. It is not a first-line panel and is not reported alongside 95004 for the same allergen without a documented reason. We confirm the percutaneous result, document the clinical indication, and bill 95028 only where the record supports the step-up.
95044 is reported per patch applied, including removal and interpretation, for contact dermatitis evaluation. Each patch corresponds to a relevant allergen from the patient's exposure history, not a generic panel. We document the exposure history, the patches applied, the readings, and the interpretation, and we confirm the unit count against the record before submission.
An oral food challenge is billed with 95075 for the single food and 95076 for each additional food, with medical necessity documented for the suspected allergy. A drug challenge or desensitization is billed with 95017 or 95018, with the drug, the indication, and the observation plan documented. We confirm the challenge type and the units before submission.
Under Medicare component coding, allergen immunotherapy is billed in two parts. The preparation and provision of the extract is billed with 95144 for a single-dose vial or 95165 for a multi-dose vial per cc, and the administration is billed separately with 95115 for a single injection or 95117 for two or more injections. We bill the preparation and the administration as distinct components, supported by the signed extract order.
95165 is billed per cc of prepared multi-dose extract, with one unit equal to one cc. A 10cc vial supports up to 10 units and a 5cc vial supports up to 5 units, and the Medicare medically unlikely edit is 30 units per day. We bill the anticipated doses, not the administered doses, track the units against the vial and the edit limit, and support the count with the signed extract order.
Sublingual immunotherapy, or SLIT, is frequently a non-covered benefit under Medicare and many commercial plans. We verify the coverage before treatment, and where it is non-covered we obtain a patient agreement and bill the patient rather than submitting a claim that will deny. We never submit SLIT as a covered service when the plan excludes it.
A therapeutic subcutaneous biologic injection, such as omalizumab or mepolizumab, is billed with 96372 for the administration, with the drug reported on its HCPCS J-code. We confirm the J-code against the current HCPCS release, since biologic J-codes are updated frequently, document the medical necessity, and obtain prior authorization where the payer requires it.
IVIG infusion is billed with 96365 for the first hour and 96366 for each additional hour, with the immune globulin reported on its HCPCS J-code. We obtain prior authorization before the infusion, document the immunodeficiency diagnosis that supports medical necessity, and confirm the J-code against the current HCPCS release, since IVIG J-codes change frequently.
Testing medical necessity is supported by the clinical indication, the relevant allergens tied to the patient's exposure history, the number of tests matching the documented allergens, and the step-up rationale when intracutaneous testing follows a negative percutaneous test. We build the documentation into the claim before submission, so a blanket panel or an unsupported step-up does not reach the payer.
Capture Every Immunotherapy Dose You Have Prepared
Allergy and immunology revenue lives in the 95165 units, the component coding split, the testing medical necessity, and the prior authorization on biologics and IVIG. We run the cycle so every line pays what it should.